CHEK2 and prostate carcinoma: Additionally, we aimed to explore the hypothesis of a possible founder effect in the origin of this CHEK2 variant by performing haplotype and age estimation analyses in PrCa patients and controls from 11 different populations included in the PRATICAL (Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome) consortium.